CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05263583
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:58.880040+00:00
Published At: 2025-01-14T00:00:00+00:00
Record Updated At: 2025-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High-grade B-cell Lymphoma", "Burkitt Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Lymphatic Diseases", "Lymphoma, High-Grade", "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma", "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma", "C-Myc Gene Rearrangement"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-14"
protocolSection.identificationModule.nctId: "NCT05263583"
protocolSection.identificationModule.officialTitle: "A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.